Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression.

Permalink
https://escholarship.org/uc/item/2jx1q8tx

Journal
Movement disorders : official journal of the Movement Disorder Society, 35(8)

ISSN
0885-3185

Authors
Christine, Chadwick W
Auinger, Peggy
Saleh, Nasrin
et al.

Publication Date
2020-08-01

DOI
10.1002/mds.28073

Peer reviewed
Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson’s Disease Progression

Chadwick W. Christine, MD,1* Peggy Auinger, MS,2 Nasrin Saleh, MD,3 Miao Tian, MD, PhD,3 Teodoro Bottiglieri, PhD,4 Erland Arning, PhD,4 Nam K. Tran, PhD,5 Per Magne Ueland, MD, PhD,5 and Ralph Green, MD, PhD,3 on behalf of the Parkinson Study Group—DATATOP Investigators**

1Department of Neurology, UCSF, San Francisco, California, USA 2Center for Health and Technology, University of Rochester, Rochester, New York, USA 3Department of Pathology and Laboratory Medicine, UC Davis, Sacramento, California, USA 4Institute of Metabolic Disease, Baylor Scott & White Research Institute, Dallas, Texas, USA 5Bevital, New Lab Building, Bergen, Hordaland, Norway

ABSTRACT: Background: Using blood specimens from untreated early Parkinson’s disease (PD) patients from the DATATOP trial, we found that subjects in the low serum vitamin B12 tertile experienced greater annualized change in ambulatory capacity score, whereas those with moderately elevated (>15 μmol/L) total homocysteine had greater annualized declines in the Mini-Mental State Exam.

Methods: In this study we sought to determine whether levels of cerebrospinal fluid (CSF) B12 markers were also associated with progression of PD.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Dr. Chadwick W. Christine, 400 Parnassus Ave., Box 0348, San Francisco, CA 94143, USA; E-mail: chad.christine@ucsf.edu

**The list of DATATOP investigators/coordinators can be found in reference 7.

Conflict of interest/financial disclosures: C.W.C. reports research grants from Voyager Therapeutics, Inc, NINDS, and from Michael J. Fox Foundation. R.G. reports a donation from an anonymous private foundation.

Funding agencies: The release of the DATATOP CSF specimens was approved by the Parkinson’s Disease Biospecimen Review Access Committee and supported by the Michael J. Fox Foundation for Parkinson’s Research, Grant 11951. Funding was provided by unrestricted gifts from the Dorskind Family and the Liu Family.

Received: 30 January 2020; Revised: 25 March 2020; Accepted: 2 April 2020

Published online 14 May 2020 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28073

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.
Results: The annualized change in the UPDRS “walking” item, a component of the ambulatory capacity score, was worse in the low B12 tertile. No association with change in the Mini-Mental State Exam was seen for those 7% with the highest baseline CSF total homocysteine.

Conclusions: In these untreated early-PD subjects, low CSF B12 predicted greater worsening of the UPDRS “walking” item, whereas CSF total homocysteine was not associated with progression of cognitive impairment. These findings extend and partially support our findings in serum. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Key Words: cognitive impairment; CSF; cyanocobalamin; gait instability; hyperhomocysteinemia; vitamin B12

In our recent investigation of vitamin B12 status in untreated early Parkinson’s disease (PD), using 680 baseline blood samples from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) cohort,1 we found that those subjects with B12 levels in the low tertile developed greater morbidity, as measured by annualized changes in the ambulatory capacity score compared with those in the middle and upper tertiles. The ambulatory capacity score is a validated measure of gait and balance function calculated as the sum of 5 Unified Parkinson’s Disease Rating Scale (UPDRS) items. Increases in the score reflect declines in gait function.2 Of equal interest, we found that those with moderately elevated total homocysteine (tHcy) had greater annualized declines in the Mini-Mental State Exam (MMSE).

Although it is possible that the association of low B12 with more rapid impairment of ambulatory capacity is mediated by its known role supporting central and peripheral nervous system myelination, recent studies have shown that B12 inhibits α-synuclein fibrillogenesis3 and that B12 allosterically modulates leucine-rich repeat kinase 2 (LRRK2),4 an enzyme implicated in PD pathogenesis, raising a disease specific mechanism of action.

Because cerebrospinal fluid (CSF) is often considered the preferred biofluid to assess central nervous system status,5,6 we sought to determine whether baseline CSF levels of B12, tHcy, and 2 other markers of B12 status, compared with previously obtained serum measurements, were more strongly associated with measures of disease progression in the DATATOP study.

Methods

DATATOP was a double-blind, randomized trial that tested whether treatment with deprenyl (selegiline hydrochloride) and/or the antioxidant alpha-tocopherol slowed PD progression. The study enrolled 800 participants between 1987 and 1988.7 Eligible subjects had early PD and were excluded if they had begun PD medications, had severe tremor, or had dementia. After the baseline visit, subjects were evaluated every 3 months up to 24 months. At each visit, subjects were assessed for disability sufficient to require levodopa therapy (the primary end point) as well as other outcomes including the UPDRS and the MMSE.2

CSF was collected at the baseline visit after overnight bed rest. At the time of collection, the CSF was rapidly frozen for storage at −70°C. We used samples obtained from the middle or end of the CSF collection, which were not stored with metabisulfite preservative.

CSF B12 was measured using a microbiological assay.8 Samples were diluted 1:4, and following an extraction step diluted a further 1:1.2 for an overall dilution of 1:4.8. Methylmalonic acid (MMA) was measured using liquid chromatography–tandem mass spectrometry (LC-MS/MS).9 Holotranscobalamin (holoTC) was determined by monoclonal antibody capture assay.10 tHcy was determined by LC-MS/MS using a modification of a previously described method.11 Separation and detection of tHcy were performed with a Nexera UPLC system (Shimadzu, Kyoto, Japan) interfaced with a 5500 QTRAP (Sciex, Framingham, MA). All data were collected and processed using Analyst software version 1.6.2 (Sciex, Framingham, MA).

The annualized change in PD-related motor scores and MMSE were determined based on the change from baseline to the primary end point or the final visit if the primary end point was not reached as previously described.1 Following mean annualized change in scores (including UPDRS, ambulatory capacity, and MMSE) by baseline serum and CSF B12, MMA, holoTC, and tHcy tertiles and threshold cutoffs were compared using linear models that adjusted for baseline value of the outcome, sex, age, and treatment group. Pearson correlation coefficients were used to assess the associations among the 4 CSF analytes and between the analogous serum and CSF analytes. Multiple comparisons were accounted for by applying the Bonferroni correction in which P < 0.004 was considered statistically significant.
15.5 ± 9.4 pmol/L, for MMA was 0.34 ± 3.9 μmol/L, and for tHcy was 58.7 ± 43.7 nmol/L (Fig. 1).

CSF analytes showed significant associations with serum analytes, although the CSF levels were substantially lower than the serum levels for all except MMA. For example, CSF B12 compared with serum B12 measurements showed a correlation coefficient (r) of 0.57, P < 0.0001; however, the mean CSF B12 level was considerably lower, about 6% of the corresponding mean serum measurement (geometric mean of CSF B12/geometric mean of serum B12). CSF holoTC had an an r of 0.67 with serum holoTC, P < 0.0001, and mean CSF holoTC was 22% of mean serum levels. CSF MMA correlated with serum MMA with an r of 0.69, P < 0.0001, and mean CSF MMA was 170% of mean serum measurement. Finally, CSF tHcy had an r of 0.74 with serum tHcy, P < 0.0001; mean CSF tHcy was 0.6% of the mean serum measurement.

The most robust correlation between CSF B12 biomarkers was found between CSF B12 and CSF holoTC (eFig. 2), with an r of 0.87, P < 0.001. Weaker inverse correlations were found for CSF B12 and CSF MMA, \( r = -0.15, P = 0.0003 \), and CSF B12 and CSF tHcy, \( r = -0.18, P \leq 0.0001 \).

**Associations of Baseline Serum and CSF Analytes With Clinical Progression**

Table 1A shows that when the 570 serum samples, for which we had corresponding CSF samples, were analyzed according to baseline B12 tertiles, those subjects in the low B12 tertile developed significantly greater impairments (higher mean change scores) in ambulatory capacity compared with the middle and upper tertiles (1.61 compared with 0.91 and 0.67 points, respectively). Table 1B shows a similar relationship according to baseline CSF B12 measurements from these same subjects. In the CSF analysis, although the annualized change in the ambulatory capacity was greater in the low tertile compared with the high tertile, this difference was not significant. However, the annualized change in UPDRS “walking” score (1 of the 5 items that make up ambulatory capacity score) was significantly greater in the low tertile compared with the changes in either the high tertile or both middle and high tertiles combined (P < 0.004 for both comparisons).

Given the strong correlation between holoTC and B12 (eFig. 2), we performed an analysis of clinical
progression according to serum and CSF holoTC. Trends for greater annualized worsening in the ambulatory capacity score according to serum and CSF levels of holoTC were observed but were not statistically significant (eTable 2). Although not statistically significant based on correction for multiple comparisons, the annualized change in the “walking” item was greater in both the low serum and low CSF holoTC tertiles, compared with the corresponding high tertile (P < 0.02; eTable 2A; P < 0.01; eTable 2B, respectively). No relationships for greater change in ambulatory capacity was found in the high serum or CSF MMA tertiles (data not shown).

Finally, we compared the change in MMSE scores according to thresholds of tHcy in serum and CSF. Although serum tHcy >15 μmol/L (39 subjects or 7%) predicted an annualized decline of 1.65 points in the MMSE compared with a 0.14-point increase in those with tHcy ≤15 μmol/L, no association was observed in those subjects with the highest 7% of CSF tHcy (eTable 3).

### Discussion

In this secondary analysis of baseline serum and CSF analyte levels from a large cohort of early untreated PD patients, we found that serum and CSF analyte levels were directly associated and that the levels of B12, holoTC, and tHcy in CSF were much lower than in serum, whereas MMA was somewhat higher, as has been reported previously for normal subjects and patients with B12 deficiency. We also confirmed that in CSF, unlike serum, holoTC and B12 are strongly correlated, consistent with prior observations that in CSF, almost all B12 is bound to transcobalamin. Finally, those with low CSF B12 had greater declines in the UPDRS “walking” item (a component of the ambulatory capacity).

To our knowledge, this study is the largest study of serum and CSF analytes relating to B12 status in any PD cohort. CSF-to-serum analyte ratios in our study were 6% for B12, 22% for holoTC, 0.6% for tHcy, and 170% for MMA and are similar to the findings in prior studies. The substantially lower levels of B12 and holoTC in the CSF are consistent with the notion that B12 is supplied to the central nervous system by serum and not by way of the CSF.

Although we had hypothesized that CSF markers might be more sensitive predictors of PD progression because of the close anatomical relationship of CSF to the brain, our results do not support this hypothesis. This finding is similar to that observed regarding serum and CSF uric acid levels, with Ascherio and colleagues finding that serum uric acid measurements were a more sensitive predictor of PD progression compared with CSF levels. Because a recent study showed that blood-CSF permeability is increased with PD progression, one explanation of why CSF levels of B12, holoTC, and tHcy are not as predictive...
as serum is that CSF levels of these analytes are raised because of increased blood-CSF permeability. Although it remains possible that higher B12 levels are a nonspecific marker of better health status, we speculate that higher B12 levels may slow deterioration of gait either by reducing the development of neuropathy/myelopathy because of its known effect on nervous system myelination or possibly by affecting PD pathogenesis by reducing LRRK2 activity. Interestingly, prior studies have shown that B12 possibly by affecting PD pathogenesis by reducing LRRK2 of its known effect on nervous system myelination or possibly by affecting PD pathogenesis by reducing LRRK2 activity.

A potential limitation of this study was that the CSF was collected more than 30 years ago and that the analytes might not be stable over this time frame. However, because the DATATOP study specified strict procedures for CSF collection and storage and prior research demonstrating stability of B12, MMA, and tHcy in frozen serum specimens for as long as 29 years, we have confidence that these CSF analyte measurements are valid.

These measurements in CSF support our prior work showing that lower serum B12 levels predict greater declines in ambulatory capacity in the DATATOP study. Further study of B12 and tHcy should be performed in contemporary PD cohorts and should also explore the relationship of B12 level with markers of LRRK2 kinase activity.

Acknowledgments: The release of the DATATOP CSF specimens was approved by the Parkinson’s Disease Biospecimen Review Access Committee and the Michael J. Fox Foundation for Parkinson’s Research, Grant 119531. Funding was provided by unrestricted gifts from the Dorskind Family Foundation and the Liu Family. Samples from the DATATOP study conducted by the Parkinson Study Group and provided by the DNA and Cell Laboratory at Indiana University with support from the Michael J. Fox Foundation for Parkinson’s Research were used in this study. We thank contributors, including all members of the Parkinson’s Study Group who collected samples used in this study as well as patients and their families, whose help and participation made this work possible.

Author Contributions

Chadwick W. Christine: research project ABC; statistical analysis AC; manuscript AB.

Peggy Auinger: research project BC; statistical analysis AB; manuscript B.

Nasrin Saleh: research project C; statistical analysis C; manuscript B.

Miao Tian: research project C; statistical analysis C; manuscript B.

Teodoro Bottiglieri: research project C; statistical analysis C; manuscript B.

Erland Arning: research project C; statistical analysis C; manuscript B.

Nam K. Tran: research project C; statistical analysis C; manuscript B.

Per Magne Ueland: research project C; manuscript B.

Ralph Green: research project AB; statistical analysis AC; manuscript AB.

References

1. Christine CW, Auinger P, Joslin A, Yelapa Y, Green R, Parkinson Study Group. Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson’s disease. Mov Disord 2018;33:762–770.

2. Parashos SA, Elm J, Boyd JT, et al. Validation of an amulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson’s Disease Rating Scale. J Parkinsons Dis 2015;5:67–73.

3. Jia L, Wang Y, Wei W, Zhao W, Lu F, Liu F. Vitamin B12 inhibits alpha-synuclein fibrillogenesis and protects against amyloid-induced cytotoxicity. Food Funct 2019;10:2861–2870.

4. Schaffner A, Li X, Gomez-Llorente Y, et al. Vitamin B12 modulates Parkinson’s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Res 2019;29:313–329.

5. Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med 2011;49:345–352.

6. Parnetti L, Gaetani L, Eusebi P, et al. CSF and blood biomarkers for Parkinson’s disease. Lancet Neurol 2019;18:573–586.

7. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 1993;328:176–183.

8. Kelleher BP, Brion SD. Microbiological assay for vitamin B12 performed in 96-well microtitre plates. J Clin Pathol 1991;44:592–595.

9. Kushnir MM, Komaromy-Hiller G, Shushan B, Urry FM, Roberts WL. Analysis of diacarboxylic acids by tandem mass spectrometry. High-throughput quantitative measurement of methyalmonic acid in serum, plasma, and urine. Clin Chem 2001;47:1993–2002.

10. Uleland M, Eftersven I, Quadros EV, et al. Direct assay for cobalamin bound to transcobalamin (holo-transcobalamin) in serum. Clin Chem 2002;48:526–532.

11. Singhal NK, Li S, Arrang E, et al. Changes in methionine metabolism and histone H3 trimethylation are linked to mitochondrial defects in multiple sclerosis. J Neurosci 2015;35:15170–15186.

12. Stabler SP, Allen RH, Barrett RE, Savage DG, Lindenbaum J. Cerebrospinal fluid methyalmonic acid levels in normal subjects and patients with cobalamin deficiency. Neurology 1991;41:1627–1632.

13. Hansen M, Brynskov J, Christensen PA, Krintel JJ, Ginsing P. Cobalamin binding proteins (haptocorrin and transcobalamin) in human cerebrospinal fluid. Scand J Haematol 1985;34:209–212.

14. van Asselt DZ, Karlietis MH, Poels PJ, de Jong JG, Wevers RA. Cobalamin binding proteins (haptocorrin and transcobalamin) in cerebrospinal fluid methylmalonic acid levels in normal subjects and patients with cobalamin deficiency. Neurology 1991;41:1627–1632.

15. Isobe C, Murata T, Sato C, Terayama Y. Increase of total homocysteine concentration in cerebrospinal fluid of patients with Alzheimer’s disease and Parkinson’s disease. Life Sci 2005;77:1836–1843.

16. Obeid R, Kostopoulos P, Knapp JP, et al. Biomarkers of folate and vitamin B12 are related in blood and cerebrospinal fluid. Clin Chem 2007;53:326–333.

17. Ascherio A, LeWitt PA, Xu K, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009;66:1460–1468.

18. Pisani V, Stefani A, Pierantozzi M, et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease. J Neuroinflammation 2012;9:188.

19. Shen L. Associations between B vitamins and Parkinson’s disease. Nutrients 2015;7:7197–7208.

20. Luthra NS, Marcus AH, Hills NK, Christine CW. Vitamin B12 measurements across neurodegenerative disorders. J Clin Mov Disord 2020;7:3. doi: https://doi.org/10.1186/s40734-020-00085-8.
A New Stimulation Mode for Deep Brain Stimulation in Parkinson’s Disease: Theta Burst Stimulation

Martin A. Horn,1 Alessandro Gulberti, PhD,1,2* Eileen Gülke, MD,1 Carsten Buhmann, MD,1 Christian Gerloff, MD,1 Christian K.E. Moll, MD,2 Wolfgang Hamel, MD,3 Jens Volkmann, MD,4 and Monika Pötter-Nerger, MD1*  

1University Medical Center Hamburg-Eppendorf, Department of Neurology, Hamburg, Germany 2University Medical Center Hamburg-Eppendorf, Department of Neurophysiology and Pathophysiology, Hamburg, Germany 3University Medical Center Hamburg-Eppendorf, Department of Neurosurgery, Hamburg, Germany 4University Hospital Würzburg, Department of Neurology, Würzburg, Germany  

*Correspondence to: PD Dr. med. Monika Pötter-Nerger, Klinik und Poliklinik für Neurologie, Universitätssklinikum Hamburg Eppendorf, Martinistraße 52, 20246 Hamburg, Germany; E-mail: m.poetter-nerger@uke.de 

Relevant conflicts of interest/financial disclosures: Nothing to report. 

Full financial disclosures and author roles may be found in the online version of this article. 

Received: 27 September 2019; Revised: 2 April 2020; Accepted: 9 April 2020 

Published online 1 May 2020 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28083 

ABSTRACT: Background and Objectives: The purpose of this study was to assess efficacy and safety of a new patterned theta burst stimulation algorithm of DBS with the aim of expanding the therapeutic window and clinical benefit in PD. 

Methods: In this single-center, randomized, double-blind, clinical short-term trial, unilateral conventional subthalamic DBS was compared with unilateral patterned stimulation algorithms with intraburst high- or low-frequency theta burst stimulation in 17 PD patients. 

Results: There were no serious adverse events with theta burst stimulation. During monopolar review, conventional subthalamic DBS and high-frequency theta burst stimulation were comparable, but low-frequency theta burst stimulation differed by requiring higher stimulation amplitudes for symptom reduction, but a larger therapeutic window. High- and low-frequency theta burst stimulation with adapted stimulation amplitude were effective in PD symptom reduction with differential effects on akinesia and tremor, depending on the theta burst stimulation mode. 

Conclusions: Theta burst stimulation is a safe and effective stimulation mode with potential future application opportunities. © 2020 International Parkinson and Movement Disorder Society 

Key Words: deep brain stimulation; Parkinson’s disease; subthalamic nucleus; therapeutic window width; theta burst stimulation 

DBS of the STN (STN-DBS) is a clinically effective therapy in Parkinson’s disease (PD).1–4 DBS is usually applied by continuous delivery of high-frequency rectangular pulses at 130 Hz through bilateral electrodes in the STN. However, with usage of this conventional DBS mode, there remain postoperative issues particularly in the long-term follow-up of increasing numbers of operated PD patients, which require DBS reprogramming in the course of the time.5,6 For specific troubleshooting or prevention of DBS-induced side effects in the long term, the new focus of interest has become the development of new algorithms of DBS. 

The purpose of this project was to assess new DBS algorithms by using patterned stimulation techniques. In this pilot trial, we first aimed to assess efficacy and safety of theta burst stimulation (TBS) algorithm of DBS. 

Materials and Methods 

The study was approved by the local Ethics Committee of the Medical Council in Hamburg (reference